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Upregulation of 2 subunit-containing (2*) nicotinic acetylcholine receptors (nAChRs) is implicated in several aspects of nicotine
addiction, andmenthol cigarette smokers tend to upregulate2* nAChRsmore thannonmenthol cigarette smokers.We investigated the
effect of long-term menthol alone on midbrain neurons containing nAChRs. In midbrain dopaminergic (DA) neurons from mice con-
taining fluorescent nAChR subunits, menthol alone increased the number of 4 and 6 nAChR subunits, but this upregulation did not
occur inmidbrain GABAergic neurons. Thus, chronicmenthol produces a cell-type-selective upregulation of4* nAChRs, complement-
ing that of chronic nicotine alone, which upregulates4 subunit-containing (4*) nAChRs in GABAergic but not DA neurons. Inmouse
brain slices and cultured midbrain neurons, menthol reduced DA neuron firing frequency and altered DA neuron excitability following
nAChR activation. Furthermore, menthol exposure before nicotine abolished nicotine reward-related behavior in mice. In neuroblas-
tomacells transfectedwith fluorescentnAChRsubunits, exposure to500nMmenthol alonealso increasednAChRnumberand favored the
formation of (4)3(2)2 nAChRs; this contrasts with the action of nicotine itself, which favors (4)2(2)3 nAChRs. Menthol alone also
increases the number of 62 receptors that exclude the 3 subunit. Thus, menthol stabilizes lower-sensitivity 4* and 6 subunit-
containing nAChRs, possibly by acting as a chemical chaperone. The abolition of nicotine reward-related behavior may be mediated
throughmenthol’s ability to stabilize lower-sensitivity nAChRs and alter DA neuron excitability.We conclude thatmenthol ismore than
a tobacco flavorant: administered alone chronically, it alters midbrain DA neurons of the nicotine reward-related pathway.
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Introduction
Tobacco use is the leading preventable cause of death in the
United States (World Health Organization, 2008). Nicotine, the
primary addictive component of tobacco products, upregulates
and changes the subunit stoichiometry of nicotinic acetylcholine
receptors (nAChRs) containing the 2* subunit (2* nAChRs)
in humans, nonhuman primates, and rodents, as well as in pri-
mary cultures and cell lines derived from these species (Breese et
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Significance Statement
Menthol, the most popular flavorant for tobacco products, has been considered simply a benign flavor additive. However, as we
showhere,menthol alone exerts several neurobiological changes.We are among the first to show thatmenthol, by itself, increases
thenumberofnicotinic acetylcholine receptors (nAChRs) in themousebrain. It does soat adose thatmatchesnicotine in its ability
to increase nAChR number. At this same dose, menthol also alters midbrain dopamine neuron function and prevents nicotine
reward-related behavior. Together, our data show that menthol is more than an “inert” flavor additive and is able to change the
function of midbrain dopamine neurons that are part of the mesolimbic reward pathway.
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al., 1997; Nashmi et al., 2007; Mukhin et al., 2008; Lester et al.,
2009; Govind et al., 2012; Srinivasan et al., 2012; Brody et al.,
2013; Henderson and Lester, 2015). Althoughmidbrain dopami-
nergic (DA) neurons dominate the nicotine reward-related path-
way, chronic nicotine does not change the4 subunit-containing
(4*) nAChR number in DA neurons of the ventral tegmental
area (VTA) or substantia nigra pars compacta (SNc) but upregu-
lates 4* nAChRs in the GABAergic neurons of the substantia
nigra pars reticulata (SNr; Nashmi et al., 2007; Xiao et al., 2009).
6 Subunit-containing (6*) nAChRs inDAneurons of the VTA
and SNc are upregulated by chronic nicotine (Henderson et al.,
2014). These changes result in increased inhibitory tone from
SNr GABAergic neurons and decreased firing frequency of VTA
and SNc DA neurons (Nashmi et al., 2007; Xiao et al., 2009). In
consequence, disinhibition and enhanced excitation lead to en-
hancedDA neuron burst firing and enhancedDA release (Sulzer,
2011; Faure et al., 2014). These changes are likely a primary con-
tributor to nicotine dependence.
Menthol is the sole remaining flavor additive that is allowed in
cigarettes, and “menthol cigarettes” are used by a third of all
smokers and a majority of African-American smokers (84%;
McCarthy et al., 1995). Recently, it was revealed that almost all
cigarettes contain menthol even if they are not explicitly labeled
as such (Ai et al., 2015). Smokers of menthol cigarettes exhibit
more 2* nAChR upregulation in several brain regions com-
paredwith nonmenthol smokers (Brody et al., 2013). It is unclear
whether this additional upregulation occurs because menthol
enhances nicotine’s pharmacology, alters the metabolism of
nicotine, or acts independently. Of note, smokers of menthol
cigarettes have more difficulty quitting when compared with
smokers of nonmenthol cigarettes (Gandhi et al., 2009).
Menthol is a negative allosteric modulator of 42 nAChRs
and a noncompetitive antagonist of 7 and 34 nAChRs, with
IC50 values of111,35, and70 M respectively (Hans et al.,
2012; Ashoor et al., 2013; Ton et al., 2015). These concentrations
probably exceed those found in vivo (Benowitz et al., 2004) and
may not explain the observations of Brody et al. (2013). It is also
suggested that menthol decreases airway irritation, and allows
smokers to inhale more nicotine; or menthol may slow the me-
tabolism of nicotine, allowing elevated concentrations of nico-
tine in the plasma (Benowitz et al., 2004; Alsharari et al., 2015).
Nevertheless, some still suggest that menthol’s ability to alter
nicotine metabolism may not be sufficient to increase plasma
levels of nicotine (Ashley et al., 2012).
Ifmenthol does increase nicotine in the plasma, thismay be an
insufficient explanation for enhanced upregulation observed in
human menthol cigarette smokers (Brody et al., 2013). Human
studies using 2-[18F]fluoro-A-85380 (binds 2* nAChRs) indi-
cate that 2* nAChR upregulation in humans is saturated with
only a few cigarettes smoked daily (Staley et al., 2006), probably
because 2* nAChRs are saturated even at nicotine concentra-
tions found in low-nicotine cigarettes (Brody et al., 2009). Men-
thol may increase nicotine concentration in human blood by
20% (Ahijevych and Garrett, 2004; Benowitz et al., 2004), and
this may be insufficient to explain the menthol effect noted in
humans (Brody et al., 2013). Thus, actions in the airways or in the
liver may not fully explain the role of menthol in nicotine depen-
dence. This led us to hypothesize that prolonged exposure to
smoking-relevant levels of menthol may act independently of
nicotine to change nAChRs. To address this hypothesis, we used
a combination of in vivo and in vitro methods to characterize
menthol’s effect on nicotine reward-related behavior and on
nAChR number, function, and stoichiometry.
Materials andMethods
Reagents. ()-Menthol (product #63670), CI-976 (product #C3743),
acetylcholine chloride (product #A6625), and ()-nicotine hydrogen
tartrate (product #1463304) were obtained from Sigma-Aldrich. All nic-
otine concentrations listed (both molarity and milligrams per kilogram)
use the “free base” convention (Matta et al., 2007), with a molecular
weight for nicotine of 162.23 g/mol. Models 1002 and 1004 osmotic
minipumps were obtained from Alzet.
Animals. All experiments were conducted in accordance with the
guidelines for care and use of animals provided by theNational Institutes
of Health, and protocols were approved by the Institutional Animal Care
and Use Committee at the California Institute of Technology. The 6-
eGFP bacterial artificial chromosome (BAC) transgenic strain used in
this study possessed six copies of the 6-eGFP BAC and has been de-
scribed previously (Mackey et al., 2012; Henderson et al., 2014). The
4-mCherry knock-in mouse strain and the 3-GFP nAChR knock-in
mouse strain have been described previously (Shih et al., 2014; Srinivasan
et al., 2016). The Gene Expression Nervous System Atlas (GENSAT)
TH-eGFP strain (Gong et al., 2003) was purchased from the Mutant
Mouse Regional Resource Center. All experiments using mice included
both sexes in approximately equal numbers. In total, 71 mice were used
to accumulate the data in this manuscript. Of those, 33 were male and 38
were female. No sex differences were noted.
Menthol dose selection.We studied effects of ()-menthol (referred to
as menthol from this point). We estimated the pharmacologically rele-
vant dose of menthol by analogy with nicotine doses used in mouse
studies. The typicalmenthol cigarette contains 1–20mgofmenthol (Ai et
al., 2015) and1 mg of nicotine (Rodgman and Perfetti, 2009). There-
fore, menthol per cigarette is 1–5 times that of nicotine for the typical
menthol cigarette, but up to 20 times greater for some menthol cigarette
brands. Steady-state and peak concentrations of nicotine, as found in
human smokers, are replicated in mice using 0.4 and 2.0 mg/kg/h doses
of nicotine, respectively (Matta et al., 2007). Conditioned place prefer-
ence (CPP) assays use 0.5mg/kg nicotine (Tapper et al., 2004). Assays for
in vivo upregulation use 2.0 mg/kg/h nicotine (Nashmi et al., 2007; Hen-
derson et al., 2014).We selected 1mg/kg and 2mg/kg/hmenthol for CPP
and in vivo upregulation assays, respectively (Figs. 1, 2). Both dose selec-
tions fall within the 1:5 menthol/nicotine ratio of a typical “menthol
cigarette.”
In vitro experiments with mouse neuroblastoma 2a (Neuro-2a) cells
and cultured midbrain neurons were performed with 500 nM menthol
(24 h and 7–10 d, respectively). We chose this concentration from pre-
liminary menthol concentration–response studies. At 50 nM menthol,
upregulation was less than at 500 nM. At 5Mmenthol, the data were too
variable for systematic study. Therefore, 500 nM menthol provided the
most consistent and robust upregulation response with nAChRs tran-
siently expressed in Neuro-2a cells.
We attempted to determine the concentration of menthol in the
mouse brain following our long-term exposure paradigm (see Figs. 1–4).
An experimental assay that could detect menthol at concentrations2.5
M in brain tissue was developed. When the assay was used on brains
from mice implanted with osmotic minipumps, no measurable amount
of menthol was detected. Therefore the menthol concentration in the
brains was2.5 M, and possibly much less.
Chronic drug administration with osmotic minipumps. Chronic men-
thol or vehicle was administered to mice using osmotic minipumps
(model 1002, Alzet) following a procedure that has been reported previ-
ously (Henderson et al., 2014). Vehicle was 60% ethanol and 40% saline.
Given the infusion rate of the osmotic minipumps (0.25 l/h), 4.2
mg/kg ethanol was delivered to mice each hour for a total of 0.1 g/kg in a
24 h period. This is 45–100-fold below the dose that has been used to
study the reinforcing effects of ethanol with C57BL/6 mice (Grahame
and Cunningham, 1997). Because the control solutions in the osmotic
minipumps also contained 60% ethanol, we have confidence that effects
attributed to menthol in this study do not include effects of ethanol.
CPP assays. An unbiased protocol was used, where nicotine (0.5 mg/
kg) was given in the white chamber on “drug” days and saline was given
in the black chamber. A standard three-chamber rectangular cage was
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used where one compartment was black with a stainless steel grid floor
and the other was white with a stainless steel mesh floor (Med Associ-
ates). The floor of the middle compartment was lined with smooth poly-
vinyl chloride tomake it a neutral zone. Lighting was equilibrated so that
there was minimal bias for any of the three chambers. The test consisted
of three stages over a 10 d period (Tapper et al., 2004). Each conditioning
period was 20 min. The interval between drug injections and condition-
ing was 1 min as mice were injected and placed directly in the condi-
tioning chamber for their 20 min training period. In the first stage, a
mouse was placed in the central compartment and allowed free access to
all chambers for 20min. During stage 2, drug injections were given in the
black (saline) or white (nicotine, dissolved in saline) chambers. Themice
received intraperitoneal drug injections in the drug-associated condi-
tioning chamber on days 2, 4, 6, and 8, and received intraperitoneal saline
injections in the saline-associated chamber on days 3, 5, 7, and 9. Drug-
naive mice that exhibited a severe bias toward one of the two condition-
ing chambers (defined as65% time spent in one chamber) during stage
1 were excluded from the study. Following exclusions, no initial bias was
observed in mice (see Fig. 3). Adult male and female C57BL/6 mice (3–6
months old) were used in CPP assays. In total, 14 males and 17 females
were used (menthol osmoticminipump group, 0.5mg/kg nicotine injec-
tion: four males, six females; vehicle osmotic mini-pump group, 0.5
mg/kg nicotine injection: four males, four females; saline only group: six
males, seven females). No sex differences were observed.
Spectral confocal imaging. Imaging mouse brain slices and cultured
Neuro-2a cells containing fluorescent nAChRs followed procedures and
instrumentation previously reported (Srinivasan et al., 2012; Henderson
et al., 2014). An Eclipse C1si laser-scanning confocal microscope
equipped with a 60 1.2 numerical aperture VC Plan Apo water objec-
tive and 32 photomultiplier tubes was used for confocal imaging. Before
an imaging session using cultured Neuro-2a cells, cell culture medium
was replaced with phenol red-free CO2-independent Leibovitz (L-15)
medium (Invitrogen). eGFP and mCherry were excited at 488 and 561
nm respectively. eGFP and mCherry fluorescence were obtained. eGFP
and mCherry fluorescence emission spectra were captured and images
were unmixed using standard spectra acquired from cells expressing
eGFP or mCherry only.
For in vivo nAChR upregulation assays, male and female 6-GFP and
4-mCherry mice (3 months old) were used. No sex differences were
observed.
Donor recovery after acceptor photobleaching. We examined Fo¨rster
resonance energy transfer (FRET) between nAChR subunits using the
acceptor photobleaching method (Nashmi et al., 2003; Drenan et al.,
2008a). FRETwas detected by recording GFP dequenching during incre-
Figure 1. Chronic menthol alone upregulates 4* and 6* nAChRs in vivo. A, Montage of 60 images from a vehicle-treated 4-mCherry mouse. Scale bar, 100 m. B, 60 images of
4-mCherry direct fluorescence in the VTA, SNc, and SNr of mice treated with vehicle or menthol (2mg/kg/h, 10 d). Scale bars, 10m.D, Montage of 60 images from a vehicle-treated6-GFP
mouse. Scale bar, 100m. E, 60 images of6-GFP direct fluorescence in the VTA and SNc of mice treated with vehicle or menthol. Scale bars, 10m. B, E, Display lookup table “fire” was used
in ImageJ. C, F, Quantification of4-mCherry and6-GFP intensities; transparent circles aremean intensities of individualmice.G, Representative TIRFM images of Neuro-2a cells transfectedwith
4-SEP and2 nAChR subunits or with6-SEP,2, and3 nAChR subunits. Menthol (500 nM) was added 24 h before imaging. Scale bars, 10m. In each panel, the left image is at pH 7.4 and
the right image is the same cell at pH5.4.H, PMIDwas quantified for SEPnAChRs. I, RNA transcript levels of4 and2nAChR subunits inNeuro-2a cells, detected byRNA sequencing, are unaffected
by 500 nM menthol treatment (24 h). For all panels, data are mean SEM; *p 0.05; **p 0.01; ***p 0.005 (unpaired t test). For all panels, number in parenthesis indicates n value.
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mental photodestruction of mCherry. Images were acquired of mCherry
bleaching at eight time points, at 10 s intervals, and at a laser excitation of
561 nm. The bleaching protocol was optimized to achieve 80% pho-
todestruction ofmCherry while still recording increases in GFP emission
at each time point. Spectral images were unmixed into their GFP and
mCherry components. GFP and mCherry components were saved in
Microsoft Excel format and fluorescence intensities were normalized to
the prebleach time point (100%). FRET efficiency (E) was calculated as
E  1  (IDA/ID), where IDA represents the normalized fluorescence
intensity of GFP (100%) in the presence of both donor (GFP) and accep-
tor (mCherry), and ID represents the normalized fluorescence intensity
of GFP in the presence of donor only (complete photodestruction of
mCherry). The ID value was extrapolated from a scatter plot of the frac-
tional increase ofGFP versus the fractional decrease ofmCherry.Data are
reported as mean  SEM. In figures representing FRET assays, only a
single imaging session is represented; however, each result has been re-
peated in3 sessions on separate days with similar or identical results.
Brain slice preparation (electrophysiology). Recordings were performed
using brain slices prepared from 7–11-week-old C57BL/6 [wild type
(WT)] mice or 6-GFP nAChR mice, using the protocol described with
some modifications (Ye et al., 2006; Xiao et al., 2009). Male and female
mice were used; but no sex differences were observed. Mice were killed
with CO2, and were subject to cardiac perfusion with ice-cold modified
glycerol-based artificial cerebral spinal fluid (GACSF) saturated with
95% O2/5% CO2 (carbogen) containing (mM) the following: 250 glyc-
erol, 2.5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 26 NaHCO3 and 11
glucose. The brain was subsequently removed and sliced with a micro-
slicer (DTK-1000, Ted Pella), while immersed in GACSF. Brain slices
were allowed to recover at 32°C in a holding chamber filled with carbo-
genated ACSF containing (mM) the following: 125 NaCl, 2.5 KCl, 1.2
NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 26 NaHCO3, and 11 glucose. One hour
later, the holding chamber with slices was placed at room temperature.
One of the slices was transferred into the recording chamber and super-
fused (1.5–2.0 ml/min) with carbogen-saturated ACSF at 32 0.5°C.
Patch-clamp electrophysiology.Neurons and Neuro-2a cells were visu-
alized with an upright microscope (BX50WI, Olympus) and near-
infrared or blue illumination (the latter for visualizing fluorescent
proteins). Whole-cell patch-clamp techniques were used to record elec-
trophysiological signals with a MultiClamp 700B amplifier (Molecular
Devices), Digidata 1322 analog-to-digital converters (Molecular De-
vices), and pClamp 9.2 software (MolecularDevices). Data were sampled
at 10 kHz and filtered at 2 kHz. A patch electrode had a resistance of 4–6
M	 when filled with intracellular solutions. Those solutions were as
follows: solution 1 (in mM, for most experiments): 135 K-gluconate, 5
KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP; solution 2
(in mM, for particular experiments as stated): 70 K-gluconate, 65 KCl, 5
Figure2. InmidbrainDAneurons, chronicmenthol does not significantly alter ACh-induced response amplitudes but accelerates their decay anddecreases thebaseline firing rate.A–D,Midbrain
slices; VTA DA neurons, bregma3.1mm. B1, B2, Fluorescent neurons in slices from6-GFPmice. C1, Currents induced by ACh puffs. C2, Baseline current-clamp traces for no drug-treated and
for menthol-treated mice. E–H, Midbrain cultures; putative DA neurons. E1–E4, Fluorescent neurons from3-GFP or TH-GFP mice. F1, Currents induced by ACh puffs. F2, Baseline current-clamp
traces for no drug-treated and for chronicmenthol-treated neurons.D1,D2,G1,G2, Summary of ACh response amplitude and decay time constant.D3, Histograms for DA neuron firing frequency for
vehicle-treated andmenthol-treatedmousebrain slices (n16 and11 for vehicle treated andmenthol treated, respectively).G3, Histograms for DAneuron firing frequency for nodrug-treated and
menthol-treated cultured neurons (n 23 and 31 for no drug treated andmenthol treated, respectively). E–H, Chronic menthol treatment with cultured midbrain DA neurons was 500 nM, 7–10
d.H, Chronicmenthol alters action potential properties ofmidbrain DA neurons.H1, Mean action potential spike waveform for a no drug-treated andmenthol-treatedmidbrain DA neuron.H2,H3,
Quantification of antipeak amplitude and action potential half-width. H2, n 12 for both no drug-treated and menthol-treated cultured DA neurons. H3, n 19 and 26 for no drug-treated and
menthol-treated cultured DA neurons, respectively. In all cases (C1, F1), arrows indicate 100ms puff of 300M ACh.D1,D2,G1,G2, For all bar graphs, number in parenthesis indicates n value. Data
are mean SEM; *p 0.05; **p 0.005 (unpaired t test).
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EGTA, 0.5 CaCl2, 10HEPES, 2Mg-ATP, 0.1GTP, and 2QX-314. The pH
of these solutions was adjusted to 7.2 with Tris-base, and their osmolarity
was adjusted to 300mOsmwith sucrose. The junction potential between
patch pipette and bath solutions was nulled just before gigaseal forma-
tion. The bath was continually perfused with ACSF. All recordings were
done at a temperature of 32 1°C.
For cultured cells, 50,000 Neuro-2a cells were plated onto sterilized
12-mm-diameter glass coverslips (Deckgla¨ser), placed in 35 mm culture
dishes, and cultured in a humidified incubator (37°C; 95% air, 5%CO2).
Cells were transfected as described below.
Acetylcholine (ACh)was dissolved in extracellular solution containing
(inmM) the following: 140NaCl, 5 KCl, 2 CaCl2, 1MgCl2, 10HEPES, and
10 glucose (320 mOsm, pH set to 7.3 with Tris-base). This solution with
dissolved AChwas puffed (0.1 or 0.3 s; 20 psi) onto voltage-clamped cells
or neurons (holding potential,65 mV). To avoid receptor desensitiza-
tion by repetitive ACh application, we applied ACh at3 min intervals
and continually perfused the recording chamber with extracellular
solution.
For concentration–response curves (see Fig. 5), drug applicationswere
performed using an Octaflow II perfusion system (0.5 s, 8 psi; ALA Sci-
entific). Curve fitting was completed with KaleidaGraph 4.5 and plotted
in Origin 10.
Total internal reflection fluorescence microscopy. Cultured Neuro-2a
cells were imaged live at 37°C in a stage-mounted culture dish incubator
(Warner Instruments) using methods and instrumentation reported
previously (Richards et al., 2011; Henderson et al., 2014). Total internal
reflection fluorescence microscopy (TIRFM) enables the visualization of
fluorescently labeled intracellular molecules within250 nm of the cell–
coverslip interface. Just before imaging, growth medium was exchanged
for extracellular solution (150mMNaCl, 4mMKCl, 10mMHEPES, 2mM
MgCl2, 2 mM CaCl2, and 10 mM glucose) adjusted to the appropriate pH
(5.4 or 7.4). Superecliptic pHluorin (SEP) was excited at 488 nmwith an
air-cooled argon laser (IMA101040ALS, Melles Griot). We acidified the
imaging dish by perfusing the bath, normally at pH7.4, with an otherwise
identical solution adjusted to pH 5.4. The plasma membrane integrated
density (PMID) was determined by taking an initial TIRFM image of
each cell at pH 7.4 followed by acidification of the solution and a subse-
quent low-pH image (pH 5.4). Low-pH images were used to demarcate
endoplasmic reticulum-localized nAChRs that were subtracted from the
total footprint to determine the PMID of nAChRs.
Neuro-2a cell culture and transient transfections. Neuro-2a cells were
cultured using standard techniques (Srinivasan et al., 2011). Cells were
plated by adding 90,000 cells to poly-D-lysine-coated 35 mm glass-
bottom imaging dishes (MatTek) and cultured in a humidified incubator
(37°C; 95% air, 5% CO2). Cells were transfected with 500 ng of each
nAChR subunit cDNA. In assays using two fluorescent variants of the
same nAChR subunit (4-GFP and4-mCherry; see Fig. 5B1,B2), 250 ng
of each subunit were used so that the total amount per subunit was 500
ng. Plasmids were mixed with 250l of Opti-MEM. Lipofectamine 2000
was separately added to 250 l of Opti-MEM. After 5 min at 24°C, DNA
and lipofectamine solutions were mixed together and incubated for 25
min at 24°C. The solutions were then added to preplated Neuro-2a cells
and incubated for 24 h. After 24 h, the Opti-MEM was removed and
replacedwith growthmedium. Fifty nanomolars filter-sterilized nicotine
was added after replacing the Opti-MEMwith standard culture medium
(623 nAChRs). For 42 nAChRs, 100 nM nicotine was present for
48 h (nicotine was added at the time of transfection and then replenished
when the media was changed). CI-976 was added (20 M) with nicotine
24 h before imaging. Cells were imaged 48 h after transfection.
We used different concentrations of nicotine (50 or 100 nM) for
623 and 42 nAChRs because we have found that robust and con-
sistent upregulation of nAChR number in TIRFM assays occurs at these
concentrations using Neuro-2a cells (Richards et al., 2011; Henderson et
al., 2014).
Cultured midbrain neurons. To culture primary midbrain neurons
from mouse embryos, ventral midbrain tissue from embryonic day 14
embryos was dissected out and cultured using previously published pro-
cedures (Srinivasan et al., 2016). Following digestion with papain (15
min at 37°C), cells were separated by DNase treatment and trituration,
and plated at a density of 100,000 cells per dish in poly-L-ornithine and
laminin-coated imaging dishes containing Neurobasal medium supple-
mented with B27, Glutamax, 1% Hyclone equine serum, and 100 M
ascorbate. Either control medium or 200 nM nicotine was added to the
culture for 2 weeks from day 7 to day 21. Media were changed every 3 d.
Recordings (peak currents, hyperpolarization-activated current, action
potential duration, and baseline firing rates) did not differ among puta-
tiveDAneurons fromWT,3-eGFP, or TH-eGFP cultures (See Table 1).
Single-cell harvesting and RNA extraction using cultured midbrain DA
neurons. Cells were harvested on day 21 in culture, following previously
reported procedures (Henley et al., 2013; Srinivasan et al., 2016). Glass
capillary tubing (Kimax-51; 1.5–1.8 mm outer diameter) was cleaned by
sonication in ethanol and then baked overnight at 200°C to inactivate
RNase. Large-bore glass micropipettes (10–30 m tip diameter) were
pulled from the tubing using a Sutter P-50 microelectrode puller. Before
harvesting, we removed the media from the culture dishes, rinsed them
with 2 ml of Dulbecco’s PBS, and replaced 1 ml of Dulbecco’s PBS re-
maining in the dish for harvesting. Individual cultured neurons were
identified using a microscope equipped with a 40 phase objective. The
pipette was positioned over the cell soma using a motorized microma-
nipulator (Sutter Instrument); the cell was aspirated into the glass mi-
cropipette using gentle suction. Themicropipette containing the cell was
immediately removed from the bathing solution, placed inside a plastic,
RNase-free microcentrifuge tube containing 1.5 l of RNase-free PBS
and 0.5 l of an RNase inhibitor solution, and its tip was broken against
the side of the tube near the bottom.We applied outward pressure to the
broken micropipette using a large-gauge syringe needle to expel the re-
maining fluid at the tip of the micropipette into the tube. The tube was
then centrifuged briefly using a desktop centrifuge and then frozen on
dry ice. Typically, 16 cells were harvested per dish over a 1 h period at
ambient temperature. The resultant mRNAs were reverse transcribed
and amplified to construct single-neuron high-yield cDNA sequencing
libraries.
Laser-capture microdissection of adult mouse SNc neurons. As previ-
ously described in detail (Henley et al., 2013), whole brains from
4-month-old male mice were collected (postmortem interval of 5
min), fresh frozen over dry ice, and stored at80°C. Midbrain cryostat
sections (20 mm) were mounted on UV-treated Zeiss membrane slides
(1.0 polyethylene naphthalate nuclease-free), air dried for 5 min, and
stained with cresyl violet for 1 min. The sections were rinsed, dried, and
then visualized under bright-field illumination at 400 magnification
on a Zeiss Palm laser capture microdissection microscope. Twenty puta-
tiveDA
 cell bodies from the SNcwere dissected usingmultiple low laser
energy pulses, and were catapulted into Zeiss 200 l adhesive caps. Cell
lysis solution (Illumina) containing 30 SMART reverse transcription
primers and quantitation controls (“spikes”) were then added into the
pool of cells before freezing.
Harvesting of RNA from Neuro-2a cells. We used a mirVana miRNA
Isolation Kit (Life Technologies) to prepare RNA samples. Cells were
processed fresh (i.e., not frozen). Media in dishes containing neuro-2a
cells transiently transfected with 4-SEP and 2 nAChR subunits were
aspirated, rinsed in 1 ml PBS, and then the PBS wash was aspirated.
Neuro-2a cells were lysed directly in the culture plate using 600 l of
lysis/binding solution. The lysate was collected with a rubber spatula and
pipetted into a tube where it was pipetted to obtain a homogenous lysate.
miRNA homogenate additive (one-tenth volume of lysate) was added to
the tube containing the lysate, vortexed, and left on ice for 10 min, and
then acid-phenol–chloroform was added at a volume equal to lysate.
Lysate was vortexed for 60 s and then centrifuged for 5min at 10,000 g
at room temperature. The aqueous phase was then removed and trans-
Table 1. Comparison of electrophysiological characteristics among cultured
midbrain neurons derived fromWT,3-eGFP, and TH-eGFPmice
Peak current amplitude Firing frequency
WT 54.4 12.3 pA 3.9 1.9 Hz
3-eGFP 46.9 8.6 pA 3.2 0.7 Hz
TH-eGFP 53.8 17.7 pA 4.1 0.8 Hz
Values are represented as mean SEM; n 9–13 neurons for each genotype.
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ferred to a fresh tube. One hundred percent ethanol was added (1.25
times the volume of lysate) to the aqueous phase. The ethanol/lysate
mixture was pipetted onto a filter cartridge and centrifuged for 15 s,
repeatedly, until all of the ethanol/lysate mixture passed through the
filter. Seven hundred microliters of miRNAWash Solution 1 was added
to the filter and the filter was centrifuged for 10 s. Five hundred microli-
ters ofWash Solution 2/3 was added to the filter and then centrifuged for
10 s (twice). One hundred microliters of preheated (95°C) elution solu-
tion was used to recover the RNA. The eluate, containing the RNA, was
stored at80°Cwith 2.5l RNase inhibitor. A TurboDNA-free Kit (Life
Technologies) was used to remove contaminating DNA from RNA
preparations.
RNA sequencing. We prepared amplified cDNA from RNA using
Clontech’s SMARTerTM Ultra Low RNA system for Illumina Sequenc-
ing (Clontech). We used Clontech’s Advantage 2 PCR system for ampli-
fication of cDNA templates by long-distance PCR. Illumina’s Nextera
DNA Sample Preparation kit with Tn5-mediated tagmentation technol-
ogy (Epicenter) was used as an in vitro transposition method to simulta-
neously fragment and tag the cDNA libraries with Illumina-compatible
sequencing primers. After quality controlmeasures of yield and fragment
length distribution were taken using the Qubit fluorometer (Invitrogen)
and the Agilent Bioanalyzer, 100 bp sequencing reads were generated on
the Illumina HiSeq instrument. Each sequencing library generated20
million unique mapping reads.
RNA sequencing computational analysis. One hundred base pair se-
quence tags were mapped to the mouse genome using TopHat 1.3.2. We
quantified transcript abundance [fragments per kilobase per million
mapped reads (FPKM)] using Cufflinks. We annotated the transcripts
with genome annotations provided by Ensembl. We conducted pairwise
comparisons and calculated statistical values using Cuffdiff, part of the
Cufflinks suite, to identify differentially expressed genes. We assessed
ontology with DAVID (Database for Annotation, Visualization and In-
tegrated Discovery; Huang da et al., 2009). Cuffdiff data with FPKM1,
a corrected p value of0.05 and a fold difference of1.5 were given as
input to Ingenuity Pathway Analysis (Qiagen) for pathway analysis.
Results
Menthol alone upregulates 4* and 6* nAChR subunits in vivo
Howdoesmenthol enhance nicotine-induced upregulation?One
possibility is that menthol upregulates nAChRs, independent
of nicotine. To test this idea, we used mice containing mCherry-
labeled 4* nAChRs or GFP-labeled 6* nAChRs and a
“chronic”menthol concentration of 2mg/kg/h for 10 d. Previous
studies show that these fluorescent nAChR subunits assemble
appropriately with nonlabeled subunits, traffic properly, and
function in amanner comparable toWT nAChRs (Nashmi et al.,
2007; Mackey et al., 2012; Henderson et al., 2014; Shih et al.,
2014). In midbrain, both DA neurons and GABAergic neurons
express4* nAChRs (Nashmi et al., 2007;Mackey et al., 2012). In
GABAergic neurons of the SNr, the fluorescence intensity of 4-
mCherry nAChRs did not change following menthol treatment
(Fig. 1A–C). In contrast, the fluorescence intensities of 4-
mCherry* nAChRs were 58.5 and 54.2% greater in VTA and SNc
neurons, respectively, when compared with those of vehicle-
treated mice (Fig. 1A–C; p 0.05).
In midbrain,90% of TH-positive neurons express 6* and
3* nAChRs; GABAergic neurons do not (Drenan et al., 2008b;
Mackey et al., 2012; Srinivasan et al., 2016). The fluorescence
intensities of 6-GFP neurons in the VTA and SNc were 75.0%
and 46.5% greater inmenthol-treatedmice when compared with
vehicle-treated mice (Fig. 1D–F; p 0.05). These data show that
menthol alone upregulates4* and6* nAChR subunits inmid-
brain DA neurons.
Given that no 4* upregulation was noted in GABAergic
neurons, menthol seems to exert some cell specificity. We have
found that nicotine also exerts a cell-specific effect as it up-
regulates 4* nAChRs in somata of GABA neurons but does
not upregulate 4* nAChRs in somata of DA neurons of the
VTA or SNc (Nashmi et al., 2007). Despite observing cell-
specific upregulation, we see that menthol and nicotine ex-
hibit different cell-specific targets: menthol upregulates 4*
nAChRs in somata of the VTA and SNc (Fig. 1) but nicotine
upregulates 4* nAChRs only in somata of GABA neurons
(Nashmi et al., 2007).
Menthol upregulates nAChRs on the PM
Using mice containing fluorescent nAChRs is an appropriate
method to study nAChR upregulation in vivo, but is not readily
amenable to study changes in nAChR number on the PM. To
study nAChR subunit upregulation on the PM, we used nAChRs
tagged to SEP, a pH-sensitive GFP analog, and TIRFM (Fig.
1G,H; Richards et al., 2011; Henderson et al., 2014; Nichols et al.,
2014).We used transient heterologous expression in the neuron-
like Neuro-2a cell line. As previously documented (Moss et al.,
2009), Neuro-2a cells express transfected proteins at lower levels
than various HEK293-derived cell lines. This allows one to con-
trol nAChR stoichiometry by varying the cDNA levels of each
plasmid, and various trafficking processes remain unsaturated, so
that individual steps can be studied in early and late exocytotic
pathways (Son et al., 2009; Srinivasan et al., 2011, 2012; Xiao et
al., 2011; Henderson et al., 2014). Neuro-2a cells also robustly
express 6* nAChRs (Henderson et al., 2014).
Cells expressing 4-SEP2 nAChRs were treated (24 h) with
no drug or with 500 nMmenthol (Fig. 1G,H).4-SEP2 nAChRs
treated with menthol exhibited a significant (p  0.05) twofold
increase in PMID (Fig. 1H). Cells transfected with 6-SEP, 2,
and3 nAChR subunits, treatedwithmenthol, exhibited a three-
fold increase in PMID (Fig. 1H), which is similar to previous
observations with 24 h nicotine treatment (Henderson et al.,
2014). We assessed gene expression on 4 and 2 nAChR sub-
units in transfected Neuro-2a cells treated with no drug or with
500 nM menthol for 24 h (Fig. 1I). We detected no change in 4
or 2 nAChR subunit transcripts in menthol-treated versus no-
drug-treated Neuro-2a cells. From these data, we conclude that
menthol alone robustly upregulates 4* and 6* nAChRs on the
PM, via post-translational mechanism(s).
Chronic menthol exposure alters native nAChR function
In addition to increasing nAChRnumber inmidbrain neurons, nic-
otine also alters the function ofmidbrain neurons of theDA reward
pathway (Nashmi et al., 2007; Xiao et al., 2009; Faure et al., 2014).
Thus, using electrophysiology,we investigated how long-termmen-
thol treatment affects the function of midbrain VTA neurons (Fig.
2). As mentioned, 6* nAChRs in the midbrain are selectively ex-
pressed in DA neurons of the VTA and SNc (Drenan and Lester,
2012; Mackey et al., 2012). We prepared brain slices from 6-GFP
mice to facilitate identification of VTADAneurons (Fig. 2A,B1,B2).
Interestingly, treatment withmenthol (2.0mg/kg, 10 d) did not sig-
nificantly change peak current amplitude (Fig. 2C1,D1), but did ac-
celerate the decay phase of nAChR currents stimulated by 300 M
ACh (100 ms puff; Fig. 2C1,D2). This functional modification of
nAChRs following chronic menthol treatment was not accompa-
nied by a significant change in baseline firing rates of VTADA neu-
rons (Fig. 2C2,D3; 4.25 0.61 and 3.85 0.88 Hz for vehicle and
menthol-treatedmice, respectively).
We also examined effects of long-term, submicromolar men-
thol (500 nM, 7–10 d) on native nAChRs using culturedmidbrain
neurons (Fig. 2E,H). To facilitate the identification of DA neu-
rons, we used primary cultures from 3-eGFP knock-in mice
2962 • J. Neurosci., March 9, 2016 • 36(10):2957–2974 Henderson et al. •Menthol, More Than a Tobacco Flavor Additive
(like 6*, selectively expressed on DA neurons of the VTA and
SNc; Shih et al., 2014) or fromTH-eGFPmice (Fig. 2E1–E4; Srini-
vasan et al., 2016). Recordings (peak currents, hyperpolarization-
activated current, action potential duration, and baseline firing
rates) did not differ among putative DA neurons from WT, 3-
eGFP, or TH-eGFP cultures (Table 1). We chose not to use cul-
tures from 6-GFP embryos because these arise from
heterozygoteWTcrosses (Mackey et al., 2012; Srinivasan et al.,
2016) and produce fewer fluorescent neurons in culture than the
available embryos from homozygote homozygote crosses (3-
eGFP). We found that the TH-eGFP cultures gave the most ro-
bust fluorescent signals and allowed for easiest identification of
putative DA neurons. Thus, the majority of electrophysiological
data were acquired using cultures from TH-eGFP mice.
In agreement with recordings from mouse brain slices, long-
term menthol significantly accelerated nAChR decay rates elic-
ited by 300 M ACh (100 ms puff; Fig. 2F1,G2) and did not alter
peak current amplitude (Fig. 2F1,G1). Menthol treatment signif-
icantly decreased baseline firing rates of midbrain DA neurons
(Fig. 2F2,G3). Additionally, we observed that menthol treatment
increased the half-width of DA neuron action potentials (p 
0.05; Fig. 2H1–H3). With mouse brain slices and cultured mid-
brain neurons, we observed no effects of menthol when applied
acutely (500 nM; data not shown).
Classical data show that nAChR agonists acutely increase fir-
ing of midbrain DA neurons (Brodie, 1991; Liu et al., 2012).
Previous data also show that this effect is blunted by chronic
nicotine treatment (Nashmi et al., 2007). Since menthol de-
creases baseline firing (Fig. 2F2,G3) similar to nicotine (Nashmi et
al., 2007; Xiao et al., 2009), we studied whether menthol also
alters the agonist-induced transient increase in DA neuron firing
frequency. ACh application (300 M, 100 ms) transiently in-
creased cultured DA neuron firing frequency (Fig. 3A1,B1,B2).
Following long-term treatment with menthol (500 nM, 7–10 d),
Figure 3. Long-termmenthol treatment prevents nAChR-induced acceleration of DA neuron firing frequency. A, Current-clamp recordings from cultured midbrain DA neurons treated with no
drug (A1) or treatedwith 500 nMmenthol over 10 d (A2) before and after an ACh puff.B1, Time course of firing frequency before and after a 100ms ACh puff. Dashed lines aremean firing frequency
for no drug-treated andmenthol-treated neurons before the ACh puff.B2, Quantification of firing frequency in no drug-treated andmenthol-treated conditions before and after ACh puff. Mean for
pre-ACh () and post-ACh (
) puff are the 3 s before and after the ACh puff. Data aremean SEM; *p 0.05; **p 0.001 (unpaired t test). In all cases, arrows indicate 100ms puff of 300M
ACh. C, Current-clamp recordings from cultured midbrain DA neurons treated with 500 nM menthol (10 d) without sulpiride (C1) or with acute exposure to 1M sulpiride (C2). In all traces, arrows
show a 100 ms puff of 300M ACh. Number in parenthesis indicates n value.
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cultured DA neurons displayed a transient decrease in firing fre-
quency following ACh application (Fig. 3A2,B1,B2). Here we see
that long-term menthol alone exerts an effect opposite to that of
long-term nicotine. Nicotine treatment permits a transient in-
crease in DA neuron firing frequency following nAChR agonist
application (Nashmi et al., 2007). Menthol treatment, in con-
trast, causes a transient decrease in DA neuron firing frequency
following nAChR agonist application. In 80% of the recordings,
culturedDAneurons were hyperpolarized following an ACh puff
(Fig. 3A2). In previous reports, midbrain DA neurons were sim-
ilarly hyperpolarized by acute DA application (Ingram et al.,
2002). To determine whether the hyperpolarization we observed
in menthol-treated DA neurons is mediated through dopamine
D2-like receptors [D2Rs, but possibly including D3 receptors
(Collo et al., 2013)], we used the D2R antagonist sulpiride. Cul-
tured midbrain DA neurons treated with 500 nM menthol (7–10
d) were recorded in current-clampmode (as in Fig. 3A1,A2,B1,B2)
and exposed to ACh (100 ms, 300 M). DA neurons were then
bath perfused with extracellular solution containing 1 M
sulpiride to block D2Rs, and then re-exposed to ACh (100 ms,
300 M; Fig. 3C1,C2). DA neurons that were hyperpolarized fol-
lowing an ACh puff (Fig. 3C1) lacked this response during
sulpiride exposure (Fig. 3C2). This suggests that menthol may
also play a role in altering DA neuron excitability via somatic DA
release that results from activation of D2Rs or activation of
G-protein-activated inward rectifier channels.
Nicotine’s ability to reduce DA neuron baseline firing fre-
quency is believed to be one contributing feature of addiction as
this may enhance the fraction of DA release during burst firing
(Sulzer, 2011). Long-term menthol’s ability to reduce baseline
firing frequency of midbrain DA neurons may cause an analo-
gous alteration in DA release. However, nAChR activation
decreases DA neuron firing frequency transiently following long-
term menthol treatment, which is opposite to what happens fol-
lowing acute nAChR activation, which has the classical effect of
transiently increasing the firing frequency of DA neurons. There-
fore long-term menthol treatment may alter nicotine reward-
related behavior. To address this, we studied effects of long-term
exposure to menthol on nicotine reward-related behavior.
Chronic menthol abolishes nicotine reward-like behavior
CPP is appropriate for studying nicotine reward-related behavior
(Tapper et al., 2004). We tested how long-term (10 d) menthol
treatment prior to nicotine exposure alters CPP. Similar to treat-
ment before microscopy and electrophysiology measurements,
mice were treated with vehicle or 2.0 mg/kg/h menthol for 10 d
using osmotic minipumps; we then began the conventional 10 d
training and testing regimen for CPP (Fig. 4A). On day 11 (after
10 d of vehicle or menthol exposure), mice were tested for initial
preference, and training began on day 12 for CPP assays using
nicotine (0.5 mg/kg). Final testing was conducted on day 20.
During the training and testing for CPP (days 11–20), mice con-
tinued to receive vehicle or menthol (Fig. 4A). Mice receiving
saline only exhibited no reward-related behavior (Fig. 4B). Mice
treated long-term with vehicle and receiving 0.5 mg/kg nicotine
in the drug-associated chamber during training exhibited a
Figure4. Chronicmenthol beforenicotineexposure abolishesnicotine reward-relatedbehavior.A, Schematic of CPPassay.Micewere implantedwithosmoticminipumps for 20d to continuously
deliver 2mg/kg/hmenthol or vehicle 10 d before and during CPP training.B, Saline controlmice did not exhibit a change in baseline preference.Mice implantedwith osmoticminipumps delivering
vehicle exhibited reward-related behavior to 0.5mg/kg nicotine, but those receivingmenthol exhibited no reward-related behavior to 0.5mg/kg nicotine. Data aremean SEM; one-way ANOVA,
F 8.28; *p 0.05, post hoc Tukey’s test. Number in parenthesis indicates n value. C, Mice exhibited no significant preference for the white or black chambers during the initial test phase.
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change in preference toward the drug-associated chamber (Fig.
4B). In contrast, mice treated long-term with menthol prior to
receiving 0.5mg/kg nicotine showed a slight change in preference
away from the drug-associated chamber (Fig. 4B). Thus, long-
term treatment with menthol displayed no measureable nicotine
reward-related behavior (Fig. 4B; p  0.05). In initial testing,
none of the mice showed a severe bias toward the black or white
chambers (Fig. 4C).
We observed thismenthol-dependent decrease or abolition of
nicotine reward-related behavior, despite recent data that simul-
taneous exposure to menthol and nicotine enhances nicotine re-
ward and reinforcement (Gandhi et al., 2009; Ahijevych and
Garrett, 2010;Wang et al., 2014). These contrasting observations
point to the fact thatmentholmay act differently alone thanwhen
combined with nicotine. To identify the mechanism of how this
may occur, we examinedmenthol’s ability to alter nAChR assem-
bly and stoichiometry.
Menthol alters 42 and 62* nAChR assembly and stabilizes
lower-sensitivity nAChRs
Previous studies show that 42 nAChRs assemble in two stoi-
chiometries: the higher-sensitivity and lower-sensitivity forms
are (4)2(2)3 and (4)3(2)2, respectively (Nelson et al., 2003;
Kuryatov et al., 2005). Similarly, 62* nAChRs assemble in at
least two forms, depending on the inclusion of a 3 subunit: the
(6)2(2)23 form has a higher agonist sensitivity than the62
form (the stoichiometry of the latter is unknown; Tumkosit et al.,
2006; Xiao et al., 2011; Henderson et al., 2014). Eponymously,
these higher-sensitivity and lower-sensitivity stoichiometries are
manifested by concentration–response curves (Nelson et al.,
2003; Kuryatov et al., 2005). We therefore studied menthol’s ef-
fect on ACh sensitivity with 42 and 62* nAChRs.
Neuro-2a cells were transiently transfected with 4-eGFP2
or 6-eGFP23 nAChRs and were treated with no drug or with
menthol (500 nM, 24 h). As expected (Nelson et al., 2003), we
observed a biphasic concentration–response curve with 4-
GFP2 nAChRs (Fig. 5A; Table 2). Following menthol exposure,
we observed a85% monophasic concentration–response rela-
tionship with an EC50 value of 95.2 M (Fig. 5A; Table 2). This
suggests that menthol shifts the stoichiometry of 42 nAChRs
toward a lower-sensitivity assembly [(4)3(2)2]. It is important
to note that the (4)3(2)2 stoichiometry also has an inherent
robust response to low agonist concentrations (Harpsøe et al.,
2011;Wang et al., 2015), for instance, those produced by nicotine
during smoking.
In cells transiently transfected with 6-GFP, 2, and 3
nAChR subunits, ACh produced a monophasic concentration–
response curve with an EC50 value of 0.2 M (Fig. 5C; Table 3),
which is similar to previous observations (Henderson et al.,
2014). Following menthol treatment, we observed a biphasic
concentration–response relationship with EC50 values of 0.17
and 65.0 M (Fig. 5C; Table 3). As noted above, multiple stoichi-
ometries of 62* nAChRs are not well characterized, but it is
likely that the two stoichiometries are 623 and 62(non-
3) nAChRs. To compare this biphasic curve to a “pure” popu-
lation of 62(non-3) nAChRs, we used a mutant 2 nAChR
subunit (2DM) that enhances exit from the endoplasmic reticu-
lum and therefore enhances PM nAChRs levels (Srinivasan et al.,
2011; Xiao et al., 2011; Henderson et al., 2014). ACh produced a
monophasic concentration–response relationship curve on
62DM nAChRs with an EC50 value of 35.9 M, resembling the
less-sensitive phase of the menthol condition’s responses (Fig.
5C; Table 3). Thus, the biphasic dose–response relationship pro-
duced by menthol likely represents a mixed population of
623 and 62 nAChRs.
In addition to using concentration–response assays, we
also used FRET to study menthol’s effect on nAChR assembly
and stoichiometry (Fig. 5B1,B2,D1,D2). Donor recovery after
acceptor photobleaching was used with Neuro-2a cells tran-
siently expressing 4-GFP4-mCherry2 nAChRs, treated
with no drug or with menthol (500 nM, 24 h). We observed an
increase in FRET between 4-GFP and 4-mCherry nAChR
subunits following 24 h treatment with menthol (Fig. 5B1,B2).
This suggests that chronic menthol treatment increases the
number of lower-sensitivity (4)3(2)2 nAChRs and supports
the results from the concentration–response studies with
42 nAChRs (Fig. 5A).
To continue studying menthol-induced changes in 62*
nAChRs, Neuro-2a cells transiently expressing 6-mCherry
23-YFP nAChRs were treated with no drug or with menthol
(500 nM, 24 h; Fig. 5D1,D2). The FRET intensity between 6-
mCherry and 3-YFP subunits decreased following 24 h men-
thol treatment (Fig. 5D1,D2). This suggests that 62*
nAChRs shift to the lower-sensitivity 62(non-3) nAChR
assembly after chronic treatment with menthol and support
our observations in the concentration–response studies with
623 nAChRs (Fig. 5C).
Previous studies show that nicotine stabilizes higher-
sensitivity 42* nAChRs (Kuryatov et al., 2005; Vallejo et al.,
2005; Srinivasan et al., 2011), and this is likely an important
mechanism involved in nicotine reward, sensitization, and toler-
ance (Tapper et al., 2004; Nashmi et al., 2007; Govind et al.,
2009). Given that menthol instead stabilizes lower-sensitivity
nAChRs, this may explain how long-termmenthol exposure, be-
fore nicotine, may prevent or abolish nicotine reward-related
behavior. It is possible that the menthol-induced stabilization of
lower-sensitivity nAChRs (Fig. 5E,F) prevents the necessary sta-
bilization and activation of higher-sensitivity nAChRs.
Long-term menthol treatment alters nAChR desensitization
To understand further how long-term menthol alone may abro-
gate nicotine reward-related behavior, we began to study addi-
tional functional characteristics of nAChRs and how they are
altered by exposure to menthol. We used Neuro-2a cells tran-
siently transfected with specific nAChRs to study 42 and
623 nAChRs. Neuro-2a cells transiently transfected with4-
eGFP2 or 6-eGFP23 nAChRs were treated with no drug or
with menthol (500 nM, 24 h). We first verified that acute admin-
istration of menthol (4 M) did not affect peak current ampli-
tude or decay kinetics of 623 nAChRs (data not shown).
Hans et al. (2012) established that acute menthol does not signif-
icantly alter42 nAChR function at4M.Menthol treatment
(24 h, 500 nM) had no effect on the peak current amplitude of
4-eGFP2 nAChRs when stimulated by 300 M ACh (Fig.
6A1,A2,B1). We also assessed whether acute exposure to menthol
altered the deactivation kinetics of 42 nAChRs using 10 s ap-
plications of 300MACh (Fig. 6B1,B2). Menthol did not alter the
shape of 4-GFP2 nAChR waveforms (Fig. 6B1), including the
decay time constant (Fig. 6B2).
Next, we assessed menthol’s effect on the functional proper-
ties of 623 nAChRs. Twenty-four hour exposure to submi-
cromolar menthol led to a significant decrease (p  0.005) in
the peak current amplitude of 6-eGFP23 nAChRs (Fig.
6C1,C2,D1). Although the peak amplitude decreased following
chronic treatment with menthol, the 6-eGFP23 nAChRs re-
tained a phase that desensitized partially, with a time constant of
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8 s (Fig. 6D1,D2). 62(Non-3) nAChRs are not preferen-
tially assembled when 3* nAChR subunits are available (Tum-
kosit et al., 2006), but they exhibit smaller peak current
amplitudes (Xiao et al., 2011; Henderson et al., 2014) that resem-
ble our observations following menthol treatment (Fig. 6C1,C2).
The decrease in peak current amplitude (Fig. 6C1,C2) is not due to
acute antagonism, but rather is likely due to the change in 6*
nAChR stoichiometry (Fig. 5).
Figure 5. Chronicmenthol alters nAChR stoichiometry and favors low-sensitivity nAChRs.A, Concentration–response curves of Neuro-2a cells transfectedwith4-eGFP2 nAChRs treatedwith
no drug (black) or with menthol (red; 24 h, 500 nM). C, Concentration–response curves of Neuro-2a cells transfected with6-eGFP,2, and3 nAChR subunits treated with no drug (black), with
menthol (red), or with6-eGFP2DM nAChRswith no drug (blue).B1,D1, Linear plot of donor dequenching versus acceptor (mCherry) photodestruction for no drug and formenthol (24 h, 500 nM)
treatments.B2,D2, Mean FRET efficiency. FRET efficiency was calculated from the linear plot shown inB1 andD1 as described previously (Drenan et al., 2008a; Nichols et al., 2014).B2,D2, Data are
mean SEM; **p 0.01; ***p 0.001 (unpaired t test). E, F, Summary ofmenthol-induced changes in nAChR stoichiometry. E,42 nAChRs assemble in two stoichiometries: (4)2(2)3 and
(4)3(2)2.We found that under no drug treatment the42 nAChR pool ismixed. Following 24 hmenthol treatment,42 nAChRs assemble almost entirely in the low-sensitivity (4)3(2)2
stoichiometry. F,623 nAChRs assemble efficiently under no drug treatment, but following 24 hmenthol treatment the receptor pool is changed to amixture of623 and62 nAChRs.
Number in parenthesis indicates n value.
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Interestingly, menthol (500 nM, 24 h) did increase 62
nAChR peak current amplitude by twofold (Fig. 7A,B1,B2).
TIRFM revealed that menthol treatment resulted in a 2-fold
increase in 6-SEP2 nAChR PMID (Fig. 7C). Here, menthol
differs from nicotine, as nicotine is unable to upregulate
62(non-3) nAChR number or function (Henderson et al.,
2014). These results support our previous observations (Fig. 5)
and suggest that menthol may selectively upregulate 62
nAChRs, causing a shift from primarily 623 nAChRs to a
mixture of 62 and 623 nAChRs.
Next we began to study how menthol may alter nAChR de-
sensitization (Fig. 6E,F). We desensitized 42 and 623
nAChRs transiently transfected in Neuro-2a cells using bath per-
fusion of 1Mnicotine. After 10min, perfusionwith nicotinewas
stopped and the nAChRs were allowed to recover for 20min. The
flow rates were kept constant for all experiments to ensure that
any differences would not be altered bywashout rates of nicotine.
The 42 nAChRs desensitized completely during nicotine ex-
posure and recovered only 20% of peak current amplitudes (Fig.
6E). Menthol-treated (24 h, 500 nM) 42 nAChRs exposed to
nicotine desensitized, but not completely, and recovered 80%
of their function (Fig. 6E).
The623 nAChRs desensitized completely during nicotine
application, then recovered to 40% of peak function (Fig. 6F).
Menthol-treated 623 nAChRs desensitized rapidly and re-
covered 60% of function (Fig. 6F). The rate of recovery, follow-
ing chronic menthol treatment, was faster when compared with
no drug treatment (p  0.05), but maximal recovery did not
differ significantly between chronic menthol and no drug treat-
ments. These data suggest that chronic exposure to menthol may
protect nAChRs from complete desensitization and provide ad-
ditional insight into how menthol alters nicotine reward-like
behavior.
Menthol action on nAChRs begins in early exocytotic pathways
Recent data show that upregulation of nAChRs by nicotine re-
quires the intracellular cycling of receptors between theGolgi and
the endoplasmic reticulum (Henderson et al., 2014). To deter-
mine whether upregulation by menthol also requires Golgi–en-
doplasmic reticulum cycling, we used a previously characterized
drug, CI-976, which inhibits coatomer protein complex I
(COPI)-mediated retrograde trafficking (Yang et al., 2011; Hen-
derson et al., 2014). Neuro-2a cells expressing 4-SEP2 and
6-SEP23 nAChRs were treated with no drug, with 500 nM
menthol, with 20 M CI-976, or with both drugs (Fig. 8A,B).
Both 4-SEP2 and 6-SEP23 nAChRs displayed an increase
in PMID following treatment with 500 nMmenthol (Fig. 8A2,B2).
Treatment with CI-976 alone did not change the basal PMID of
either 4-SEP2 or 6-SEP23 nAChRs (Fig. 8A2,B2). Follow-
ing treatment with both menthol and CI-976, we observed no
increase in the PMIDof4-SEP2 or6-SEP23 nAChRs (Fig.
8A2,B2). This suggests that, like effects of nicotine, the increase of
nAChR number produced by menthol requires the cycling of
nAChRs between the Golgi and endoplasmic reticulum.
Nicotine upregulates nAChRs by binding to and chaperoning
nAChRs located in the endoplasmic reticulum (Kuryatov et al.,
2005; Sallette et al., 2005; Henderson and Lester, 2015). The later
exocytotic machinery then moves these nAChRs to the PM
(Whiteaker et al., 1998; Sallette et al., 2005; Srinivasan et al.,
2011). The formation of endoplasmic reticulum exit sites (ERES)
with nicotine is an indicator of an event closely following the
nAChR chaperoning process. To determine whether menthol
causes a similar increase in ERES, we quantified the formation of
condensed ERES following chronic treatment withmenthol (Fig.
8C,D). Neuro-2a cells were cotransfected with 4-mCherry2 or
6-mCherry23 nAChRs andwith Sec24D-eGFP (amarker for
active ERES) and the density of 4-mCherry* and 6-mCherry*
nAChRs inside ERESwas calculated (Fig. 8C,D).Menthol elicited
a twofold increase of 42 nAChRs in ERES (p  0.05) and a
threefold increase in 623 nAChRs in ERES (p  0.005; Fig.
8D). Thereforementhol, like nicotine, increases ERES in addition
to the increase in nAChR number.
TRP channels do not mediate chronic menthol effects on nAChRs
Menthol is most known as a potent ligand for TRP channels.
While we believe that the actions we observed in mouse brain
slices, cultured neurons, and heterologous systems arise, directly
or indirectly, from effects on nAChRs, we devised experiments to
determine whether TRP channels also played a role (Table 4).
We usedRNA sequencing to assess the presence ofmRNAs for
TRP channels in adult mice, cultured midbrain neurons, and
Neuro-2a cells. In laser-capture microdissected DA neurons
from the SNc of adult mice, we detected mRNA from 10,000
genes at levels0.1 FPKM (Henley et al., 2013). We also identi-
fied DA neurons in cultures from embryonic mouse midbrains,
using either TH-eGFPmice fromGENSAT (Gong et al., 2003) or
nAChR 3-GFP mice (Shih et al., 2014; as in Fig. 3). In these
cultured DA neurons, we detected mRNA for 8000 genes at
levels0.1 FPKM (Henley et al., 2013; Srinivasan et al., 2016). In
DA neurons from both adult mouse and midbrain cultures,
TRPA1, TRPV1, and TRPM8 transcript levels were0.1 FPKM.
In Neuro-2a cells, TRPA1, TRPV1, and TRPM8 were not de-
tected (Table 4). Because mRNAs for the major TRP channels
sensitive to menthol are undetectable, we conclude that the ob-
served effects with menthol in mouse brain (Figs. 1, 2), cultured
DA neurons (Figs. 2, 3), or Neuro-2a cells (Figs. 1, 5–8) were not
mediated by TRP channels.
Table 2. Concentration–response analysis reveals that chronic menthol alters
42 nAChR stoichiometry
Treatment condition
4-GFP2 no drug 4-GFP2
menthol
EC50 value (higher sensitivity) 1.8 3.1M 7.8 4.9M
nh (higher) 0.645 0.57
EC50 value (lower sensitivity) 41.9 4.7M
a 95.2 14.0Ma,b
nh (lower) 2.2 2.2
Higher fraction 0.49 0.14
Values are represented as mean SEM.
aEC50 values are statistically different from HS4-GFP2 nAChRs (no drug). p 0.005, unpaired t test.
bEC50 values are statistically different from lower-sensitivity4-GFP2 nAChRs (no drug). p 0.005, unpaired t
test.
Table 3. Concentration–response analysis reveals that chronic menthol alters
62* nAChR stoichiometry
Treatment condition
6-GFP, 2,3
no drug
6-GFP2DM
no drug
6-GFP, 2,3

menthol
EC50 value (higher
sensitivity)
0.20 0.07M — 0.17 0.04M
nh (higher) 1.01 — 0.78
EC50 value (lower
sensitivity)
— 35.9 20.7Ma 65.0 4.7Ma
nh (lower) — 0.79 2.3
Higher fraction — — 0.43
Values are represented as mean SEM.
aEC50 values are statistically different from6-GFP23 nAChRs (no drug). p 0.005, unpaired t test.
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Wealso experimentedwith icilin, a well characterized TRPM8
and TRPA1 ligand. In Neuro-2a cells expressing 4SEP-2
nAChRs, we tested five icilin concentrations ranging from 50 to
20M, applied for 24 h. Icilin had no significant effect on nAChR
number (Fig. 9). Therefore, we believe that the effects of chronic
exposure to 500 nM menthol (Figs. 1G,H, 5–8) are not mediated
by TRP channels.
Discussion
Does menthol abolish nicotine reward-related behavior?
Interestingly, menthol applied long-term before nicotine expo-
sure inhibits nicotine reward-related behavior. Long-term nico-
tine exposure results in several well characterized neurobiological
and pharmacological consequences: (1) nAChR numbers are in-
creased (Richards et al., 2011; Srinivasan et al., 2011; Henderson
et al., 2014); (2) the “upregulated” nAChRs exhibit a higher sen-
sitivity to nicotine (Kuryatov et al., 2005; Govind et al., 2012;
Henderson and Lester, 2015); and (3) the cell-specific upregula-
tion leads to changes in reward-related DA release (Nashmi et al.,
2007; Sulzer, 2011; Faure et al., 2014). Additionally, activation of
these higher-sensitivity nAChRs is likely both necessary and suf-
ficient to initiate nicotine reward-related behavior (Tapper et al.,
2004; Nashmi et al., 2007; Faure et al., 2014).
We observed that menthol, in the absence of nicotine, exerts
changes in nAChR number, assembly, and function, which differ
from sequelae previously described for nicotine. Menthol’s ac-
tions on nAChR assembly are opposite to the actions of nicotine.
Figure 6. Long-termmenthol decreases623 nAChR peak current amplitude and alters4* and6* nAChR desensitization. A1,B1, C1,D1, Meanwaveforms recorded fromNeuro-2a cells
expressing6-eGFP23 or4-eGFP2 nAChRs in the absence or presence ofmenthol (24 h, 500 nM).A1, C1, 300ms puff of ACh.B1,D1, 10 s puff of ACh.B1, 10 s puffs reveal a sustained rebound
current that is likely caused by recovery from agonist-mediated channel block. A2, C2, Mean of peak amplitude of 300 ms puffs. B2, D2, Mean decay time constants for 10 s puffs. Numbers in
parenthesis indicate n value. E, F,4-GFP2 and6-GFP23 nAChRs treated with no drug (black) or with menthol (green). nAChRs were desensitized with 1M nicotine (10 min) and then
allowed to recover. In all panels, data are mean SEM; *p 0.05; ***p 0.005 (unpaired t test). In all cases, menthol treatment was 24 h, 500 nM. In all cases, menthol-containing media was
removed at the start of assays. Number in parenthesis indicates n value.
2968 • J. Neurosci., March 9, 2016 • 36(10):2957–2974 Henderson et al. •Menthol, More Than a Tobacco Flavor Additive
Instead of stabilizing higher-sensitivity nAChRs, menthol stabi-
lized lower-sensitivity nAChRs, according to our observations.
Menthol also exhibited cell-specific upregulation of midbrain
4* nAChRs that differs from effects of nicotine. Nicotine ro-
bustly upregulates 4* nAChRs on SNr and VTAGABA neurons
(Nashmi et al., 2007); in contrast, menthol upregulates 4*
nAChRs on SNc and VTA DA neurons (Fig. 10). The nicotine-
induced, cell-specific upregulation of 4* nAChRs on GABAer-
gic neurons provides an increased inhibitory tone on midbrain
DA neurons of the VTA and SNc (Nashmi et al., 2007; Xiao et al.,
2009). This increased inhibition results in decreased activity of
the target DA neurons and a decrease in tonic DA release in the
nucleus accumbens. Acute nicotine exposure causes a rebound
disinhibition that results in increased phasic DA release, driving
reward and reinforcement (Faure et al., 2014). Since menthol
does not alter 4* nAChR number on GABAergic neurons of the
SNr but upregulates nAChRs on DA neurons of the VTA and
SNc, it is possible that nicotine’s circuit-based effect onmidbrain
GABA and DA neurons is partially negated.
The different pharmacology of high-sensitivity and low-
sensitivity nAChRs presumably plays a role. Higher-sensitivity
nAChRs (stabilized by nicotine) are robustly activated by low
concentrations of nicotine (1M; Nelson et al., 2003; Kuryatov
and Lindstrom, 2011). Lower-sensitivity 4* and 6* nAChRs
(stabilized by menthol) are robustly activated by concentrations
of nicotine30M (Fig. 5). However, circulating concentrations
of nicotine in human smokers (and mice following our adminis-
tration protocol) are 100–500 nM. This suggests that long-term
menthol alonemay reduce the efficacy of circulating nicotine and
its acute effects.
We note that menthol altered midbrain DA neurons so that
transient nAChR activation results, via D2R, in a decrease in DA
neuron firing frequency (Fig. 3). This appears to oppose the ac-
tions of nicotine (Fig. 10). In summary, long-termmenthol treat-
ment alone may reduce or prevent the “burst-like” firing due to
nAChR activation by nicotine, important for reward and rein-
forcement. Reduced burst-like firing may contribute to our
findings that menthol alone prevents nicotine reward-related
behavior.
These observations occurred with chronic exposure to men-
thol alone, or in the case of our behavioral studies, menthol alone
followed by nicotine during continued maintained exposure to
menthol. In other studies, when previously menthol-naive ani-
mals are repeatedly coexposed to nicotine plus menthol, there is
an enhancement of nicotine reinforcement (Wang et al., 2014)
and nicotine withdrawal (Alsharari et al., 2015). Experiments are
necessary, and underway, to understand additional cellular and
behavioral effects of coexposure to nicotine plus menthol.
Menthol may act directly on midbrain DA neurons
Previous data show thatmenthol acts in the lungs (Ahijevych and
Garrett, 2010) and alters nicotine metabolism in humans (Be-
nowitz et al., 2004) and mice (Alsharari et al., 2015). Because we
observedmarked effects by chronic menthol on nAChR function
Figure 7. Menthol upregulates62(non-3) nAChRs. Neuro-2a cells were transfectedwith6-eGFP and2 nAChR subunits.Where indicated,menthol (500 nM)was present for 24 h before
imaging. A, Representative traces showing 300M ACh-induced currents for cells treated with no drug or with menthol (24 h, 500 nM). B1, B2, Summary of peak current and percentage of cells
exhibiting function. C1, Representative TIRF images. Scale bars, 10m. In each panel, left image is at pH 7.4 and right is the same cell imaged at pH 5.4. C2, Mean PMID (mean SEM).B1, C2, *p
0.05, unpaired t test. Number in parenthesis indicates n value.
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with mice and with cultured DA neurons in the absence of nico-
tine, we conclude that menthol exerts a neural effect(s) by itself,
in addition to modifications that may occur when nicotine is
present. In using osmoticminipumps to delivermenthol tomice,
we largely avoid the pharmacokinetics of exposure through the
lungs. We infer that menthol enters the mouse brain and is pres-
ent at2.5M after 10 d. Due to our present detection limits, we
cannot provide a true concentration ofmenthol inmouse brains.
Thiswas onemotivation to employ culturedmidbrain neurons to
study the function of native nAChRs on DA neurons with a
known concentration of menthol; we observed local actions of
menthol at 500 nM. Therefore, if menthol alters nicotine metab-
olism or levels of nicotine, this augments the local actions of
menthol alone on midbrain neurons.
Menthol as a candidate chemical chaperone
Our data show that chronic exposure to low-dose menthol acts
on processes also influenced by chronic exposure to low-dose
nicotine. These actions occur at the subcellular level, the cellular
level, and the behavioral level; but actions differ between nicotine
and menthol (Fig. 10). Many mechanistic facts are available
about so-called “inside-out” actions of chronic nicotine begin-
ning when nicotine acts as a selective pharmacological chaperone
by binding to highly nicotine-sensitive nAChRs within the endo-
plasmic reticulum and cis-Golgi (Henderson and Lester 2015).
Several thermodynamic, pharmacokinetic, and pharmacody-
namic properties allow nicotine to function in this way at con-
centrations orders of magnitude lower than the EC50 value for
transiently activating nAChRs on the PM. Now we report that
exposure to menthol also appears to act within the early exocy-
totic pathway, atmaintained concentrations orders ofmagnitude
Figure 8. Long-termmenthol upregulates nAChRs via endoplasmic reticulum–Golgi trafficking.A1,A2, Representative TIRFM images of Neuro-2a cells transfectedwith4-SEP plus2 or with
6-SEP plus2 plus3 nAChR subunits. Nicotine (50 or 100 nM), menthol (500 nM), or CI-976 (20M) were present 24 h before imaging. Scale bars, 10m. In each panel, the left image is at pH
7.4 and right image is the same cell at pH 5.4. B1, B2, PMID was quantified for SEP nAChRs. C1–C4, Representative confocal images of a Neuro-2a cell transfected with6-mCherry,2, and3
subunits plus Sec24D-eGFP. Scale bars, 5m. C1, Sec24D-eGFP fluorescence. C2,6 Fluorescence. C3, Merged C1 and C2 image. C4, ERES demarcated for quantification. D, Quantification of the
4-mCherry or6-mCherry fluorescence in ERES. Data are mean SEM. *p 0.05; **p 0.005 (ANOVA, post hoc Tukey’s test). Number in parenthesis indicates n value.
Table 4. mRNA profile of TRP family genes
Gene
Whole
brain
Laser-captured single
DA neurona
Single cultured
DA neuron
Neuro-2a
cells
TRPM8b    
TRPA1b    
TRPV1    
TRPV2 
 
 
 

TRPM2 
 
 
 

TRPM7 
 
 
 

TRPC2 
 
 
 

TRPMl1 
 
 
 

aFrom SNc of adult mouse brain.
bA TRP family gene encoding a menthol-activated channel.

,1.0 FPKM.
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Figure 9. TrpM8 agonist icilin does not alter PM nAChR number. A1, B1, Representative TIRFM images of Neuro-2a cells transfected with4-SEP2 and6-SEP23 nAChRs. Icilin, at listed
concentrations, was present 24 h before imaging. Scale bars, 10m. In each panel, the left image is at pH 7.4 and the right image is the same cell at pH 5.4. A2, B2, PMID was quantified for SEP
nAChRs. Number in parenthesis indicates n value.
Figure 10. Chronicmenthol and chronic nicotine differentially altermidbrain DA neurons. Schematic of nAChRs residing inmidbrain GABA (SNr) andDA (VTA and SNc) neurons. Nicotine robustly
increases higher-sensitivity4* nAChR number in SNr GABAergic neurons, but does not change4* nAChR number in SNc or VTA DA neurons (Nashmi et al., 2007; Xiao et al., 2009). Long-term
nicotine exposure decreases firing frequency of DA neurons, but this is transiently accelerated upon exposure to nAChR agonists (i.e., nicotine; Nashmi et al., 2007; Xiao et al., 2009). Long-term
menthol exposure increases lower-sensitivity4* and6* nAChR number in SNC and VTA DA neurons, but does not alter SNr GABAergic4* nAChR number. DA neuron firing frequency, which
decreases following long-termmenthol exposure, does not accelerate following exposure to nAChR agonists. The opposing effects of nicotine and menthol on midbrain neurons may explain how
long-termmenthol treatment before nicotine exposure abrogates nicotine reward-related behavior.
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lower than the effective concentrations for transient activation of
TRPM8 or for allostericmodulation of Cys-loop receptors (Hans
et al., 2012; Ashoor et al., 2013; Ton et al., 2015).
We ruled out participation by TRPM8 or TRPA1, and these
concentrations of menthol produce no acute effects on the two
classes of nAChRs studied here (Hans et al., 2012). We do not
believe that menthol is acting as a selective pharmacological
chaperone for nAChRs. “Chemical chaperoning” may more ap-
propriately describe effects of chronic menthol exposure at
nAChRs. Chemical chaperones, such as butyrate, 4-pheylbutyric
acid, and valproic acid, stabilize partially or improperly folded
proteins. These compounds do increase the expression of
nAChRs, mostly at micromolar concentrations (Sine et al., 1990;
Kuryatov et al., 2013), via post-translational mechanisms. In one
case, valproic acid upregulated 7 nAChRs in neuroblastoma
cells at concentrations just 10-fold higher than the menthol con-
centrations studied here (Kuryatov et al., 2013). The present data
are novel in providing information that a tobacco additive asso-
ciated with nicotine dependence stabilizes certain nAChR stoi-
chiometries, that the upregulation occurs in vivo, and that the
changes have behavioral components.
From electrophysiology and FRET assays, this study shows
that menthol alone stabilizes lower-sensitivity 4* and 6*
nAChRs. In this effect, menthol phenomenologically resembles
the nAChR partial agonist cytisine or the endogenous protein
lynx1, which also stabilize lower-sensitivity (4)3(2)2 nAChRs
(Richards et al., 2012; Srinivasan et al., 2012; Nichols et al., 2014).
It is possible that menthol acts like lynx1, which binds to and
stabilizes– nAChR interfaces and acts as a chaperone for these
–-containing nAChRs. The FRET methods in this paper are
dominated by the nAChRs residing in the endoplasmic reticulum
and Golgi, with additional contribution from the PM. Therefore,
we know that the receptors existing in the early secretory pathway
are also lower-sensitivity (4)3(2)2 and62(non-3) nAChRs
following menthol exposure.
However, we lack data proving thatmenthol exerts its chronic
actions on nAChRs by binding directly to those nAChRs. Chem-
ical chaperones have less selective actions than pharmacological
chaperones. It is prudent to suppose that menthol binds directly
to several proteins, perhaps including nAChRs. In particular, we
do not yet know how chronic menthol exposure produces strong
coupling between nAChR activation and D2R-mediated GIRK
activation.
Although “vehicle” solutions contained ethanol, one asks
whether the 60% ethanol in the osmotic minipumps interacted
with the menthol delivered from those pumps. The calculated
plasma ethanol concentration was 45–100-fold lower than that
affecting reward-related pathways in other reports (see Materials
and Methods). For the cell culture experiments, there was no
ethanol. The extensive biochemical and pharmacological corre-
spondences among the in vivo experiments and cultures argue
against a synergistic interaction, at the behavioral level, between
ethanol and menthol.
Menthol, more than a tobacco flavorant
According to the estimate that 30% of the 15 billion cigarettes
consumed daily contain menthol, and the assumption that they
contain on average 3 mg apiece, one calculates that smokers in-
hale 15 tons of menthol daily. Along with nicotine, menthol is
one of the most inhaled substances on Earth. We have observed
that menthol alone can upregulate nAChRs, decrease DA neuron
baseline firing, alter nAChR stoichiometry, alter nAChR desensi-
tization, increase endoplasmic reticulum exit of nAChRs, and
suppress nicotine reward-related behavior. We have observed
these effects at estimated pharmacologically relevant levels of
menthol, acting locally on midbrain DA neurons relevant to
reward-related pathways. Others have shown that menthol may
enhance nicotine reinforcement (Wang et al., 2014) and nicotine
withdrawal (Alsharari et al., 2015). Thus, emerging data show
that menthol may not be just a harmless tobacco additive.
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